Program
triptorelin
Also written as “Triptorelin embonate 22.5 mg”, “Triptorelin (Decapeptyl®)” and “Decapeptyl® SR 22.5mg”.
Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Ovarian Hyperstimulation Syndrome, led by 5 companies.
Drug pageTriptorelin: every studyMany companies study it; this page follows only the 20 they lead. All 102 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ipsenits history only | 130 open or running | phase 4since Aug 23, 2012 | Dec 21, 2006 | none ahead |
| Debiopharmits history only | 30 open or running | phase 3since Sep 11, 2008 | Sep 11, 2008 | none ahead |
| Foresee Pharmaceuticalsits history only | 20 open or running | phase 3since Jan 22, 2025 | Jan 22, 2025 | none ahead |
| AbbVieits history only | 10 open or running | phase 4since Jul 9, 2010 | Jul 9, 2010 | none ahead |
| Pharmatechits history only | 10 open or running | phase 4since May 8, 2012 | May 8, 2012 | none ahead |
Also a collaborator on its studies: QPS and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Dec 21, 2006.
- Nov 24, 2009Phase 3 study in Prostatic NeoplasmsIpsen · NCT01020448 · 339 enrolled · Belgium, Denmark, France and more
- Jul 9, 2010AbbVie’s first study: phase 4 study in Prostatic NeoplasmsNew to AbbVieAbbVie · NCT01161563 · 118 enrolled · United States
- Dec 8, 2010Phase 2 study in Prostatic NeoplasmsIpsen · NCT01257425 · 109 enrolled · Germany
- Jun 14, 2011Phase 2 study in Prostatic NeoplasmsIpsen · NCT01374087 · 32 enrolled · Spain
- Nov 7, 2011Phase 3 study in Puberty, PrecociousDebiopharm · NCT01467882 · 44 enrolled · United States, Chile, Mexico
- May 8, 2012Pharmatech’s first study: phase 4 study in Prostatic NeoplasmsNew to PharmatechPharmatech · NCT02749825 · 41 enrolled · United States
- Jul 31, 2012Phase 3 study in Prostatic NeoplasmsDebiopharm · NCT01656161 · 120 enrolled · South Africa
- Aug 23, 2012Phase 4 study in Prostatic NeoplasmsIpsen · NCT01673984 · 27 enrolled · United Kingdom
- Oct 24, 2012Phase 3 study in Prostatic NeoplasmsIpsen · NCT01715129 · 126 enrolled · Bulgaria, France, Latvia and more
- Dec 17, 2012Phase 4 study in Prostatic NeoplasmsIpsen · NCT01753297 · 226 enrolled · China, Russian Federation
- Jan 29, 2021Phase 3 study in Puberty, PrecociousIpsen · NCT04736602 · 32 enrolled · China
- Aug 9, 2021Phase 3 study in Puberty, PrecociousIpsen · NCT05029622 · 66 enrolled · China
- Jun 17, 2022Phase 3 study in Prostatic NeoplasmsIpsen · NCT05458856 · 147 enrolled · Belgium, Czechia, France and more
- Jan 22, 2025Foresee Pharmaceuticals’ first studies: 2 phase 3 studies in Prostatic NeoplasmsNew to Foresee PharmaceuticalsForesee Pharmaceuticals · NCT06795191, NCT06795178
TargetBeta
“A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH)”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Goserelinrule | AstraZeneca | phase 4 | 14 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06795191Prostatic Neoplasms | 3 | Withdrawn | Foresee Pharmaceuticals | Nov 30, 2027 | 0 |
| NCT06795178Prostatic Neoplasms | 3 | Withdrawn | Foresee Pharmaceuticals | Dec 31, 2027 | 0 |
| NCT05458856Prostatic Neoplasms · Belgium, Czechia, France and more | 3 | Completed | Ipsen | Jul 8, 2024 | 147 |
| NCT05029622Puberty, Precocious · China | 3 | Completed | Ipsen | Aug 21, 2022 | 66 |
| NCT04736602Puberty, Precocious · China | 3 | Completed | Ipsen | Feb 9, 2022 | 32 |
| NCT01753297Prostatic Neoplasms · China, Russian Federation | 4 | Completed | Ipsen | Sep 9, 2019 | 226 |
| NCT01715129Prostatic Neoplasms · Bulgaria, France, Latvia and more | 3 | Completed | Ipsen | Oct 2013 | 126 |
| NCT01673984Prostatic Neoplasms · United Kingdom | 4 | Terminated | Ipsen | Feb 2014 | 27 |
| NCT01656161Prostatic Neoplasms · South Africa | 3 | Completed | Debiopharm | Aug 2013 | 120 |
| NCT02749825Prostatic Neoplasms · United States | 4 | Terminated | Pharmatech | May 2006 | 41 |
| NCT01467882Puberty, Precocious · United States, Chile, Mexico | 3 | Completed | Debiopharm | Aug 2013 | 44 |
| NCT01374087Prostatic Neoplasms · Spain | 2 | Terminated | Ipsen | Dec 2014 | 32 |
| NCT01257425Prostatic Neoplasms · Germany | 2 | Completed | Ipsen | Feb 2012 | 109 |
| NCT01161563Prostatic Neoplasms · United States | 4 | Completed | AbbVie | Apr 2011 | 118 |
| NCT01020448Prostatic Neoplasms · Belgium, Denmark, France and more | 3 | Completed | Ipsen | Nov 2011 | 339 |
| NCT00909844Puberty, Precocious · France | 3 | Completed | Ipsen | Apr 2015 | 35 |
| NCT00751790Prostatic Neoplasms · South Africa | 3 | Completed | Debiopharm | Aug 2007 | 120 |
| NCT00564850Puberty, Precocious · France | 3 | Completed | Ipsen | Oct 2010 | 37 |
| NCT00444639Prostatic Neoplasms · Netherlands | 2 | Terminated | Ipsen | Feb 2008 | 25 |
| NCT00415246Prostatic Neoplasms · Belgium, France, Latvia and more | 3 | Terminated | Ipsen | 100 |
How it is read
Names in the registry
- “Triptorelin embonate 22.5 mg”, 2 entries
- “Triptorelin (Decapeptyl®)”, 2 entries
- “Decapeptyl® SR 22.5mg”, 1 entry
- “Triptorelin Mesylate”, 1 entry
- “FP-014”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 15 studies
- Puberty, Precocious, 5 studies
- Ovarian Hyperstimulation Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.